The Iraqi Board for Medical Specializations
  • Register
  • Login

Iraqi Postgraduate Medical Journal

Notice

As part of Open Journals’ initiatives, we create website for scholarly open access journals. If you are responsible for this journal and would like to know more about how to use the editorial system, please visit our website at https://ejournalplus.com or
send us an email to info@ejournalplus.com

We will contact you soon

  1. Home
  2. Volume 8, Issue 4
  3. Authors

Current Issue

By Issue

By Subject

Keyword Index

Author Index

Indexing Databases XML

About Journal

Aims and Scope

Editorial Board

Advisory Board

Editorial Staff

Publication Ethics

Indexing and Abstracting

News

Cytogenetic Response of Peripheral Blood in Chronic Myeloid Leukemia Patients Treated With Imatinb

    Maysaa Abdul Razaq Dhahi Daad Imad Nidhal Abdul Mohaymen Nabeel Salman Murad

Iraqi Postgraduate Medical Journal, 2009, Volume 8, Issue 4, Pages 356-362

  • Show Article
  • Download
  • Cite
  • Statistics
  • Share

Abstract

ABSTRACT:
BACK GROUND:
Chronic myeloid leukemia (CML) is a stem cell disorder associated with an acquired chromosomal abnormality, Philadelphia chromosome (Ph), which arises from the reciprocal translocation of part of long arm of chromosome 9, in which proto-oncogene ABL gene (ablson) is located, to long arm of chromosome 22, in which BCR gene (break point cluster region) is located forming BCR-ABL fusion gene. The suppression of BCR-ABL is likely to be crucial for therapeutic success. The development of the BCR-ABL-targeted Imatinib mesylate represents a paradigm shift in the treatment of CML.
OBJECTIVE:
This is a prospective study designed as a try to apply cytogenetic technique as a conformational diagnosis of Philadelphia chromosome (Ph) in CML patients and also, to follow up CML patients treated with imatinib mesylate (IM) for assessment of cytogenetic response of peripheral blood at different IM treatment duration.
METHODS:
Prephral blood samples were collected from CML patients every 3-6ms. At first, (310) prephral blood(PB) samples related to 135 CML patients were cultured but only 181(58 %) cultures related to (42) patients were successful (gave obvious metaphases). The degree of cytogenetic response of peripheral blood was quantified according to the proportion of Philadelphia chromosome positive metaphases.
RESULTS:
The results showed that (64.28%) of CML achieved major peripheral blood cytogenetic response while (35.71%) achieved partial cytogenetic response.
CONCLUSION:
Conventional cytogenetic karyotyping is necessary for Ph–chromosome detection and also, as an assay for periodical assessment of cytogenetic response in CML patients treated with imatinib. Imatinib has resulted in cytogenetic responses in first line IM treated patients and in those who have failed previous IFN-α therapy and in CML patients at early and late chronic phase.
Keywords:
    chronic myeloid leukemia philadelphia chromosome Imatinib cytogenetic response
  • PDF
  • XML
(2009). Cytogenetic Response of Peripheral Blood in Chronic Myeloid Leukemia Patients Treated With Imatinb. Iraqi Postgraduate Medical Journal, 8(4), 356-362.
Maysaa Abdul Razaq Dhahi; Daad Imad; Nidhal Abdul Mohaymen; Nabeel Salman Murad. "Cytogenetic Response of Peripheral Blood in Chronic Myeloid Leukemia Patients Treated With Imatinb". Iraqi Postgraduate Medical Journal, 8, 4, 2009, 356-362.
(2009). 'Cytogenetic Response of Peripheral Blood in Chronic Myeloid Leukemia Patients Treated With Imatinb', Iraqi Postgraduate Medical Journal, 8(4), pp. 356-362.
Cytogenetic Response of Peripheral Blood in Chronic Myeloid Leukemia Patients Treated With Imatinb. Iraqi Postgraduate Medical Journal, 2009; 8(4): 356-362.
  • RIS
  • EndNote
  • BibTeX
  • APA
  • MLA
  • Harvard
  • Vancouver
  • Article View: 83
  • PDF Download: 69
  • LinkedIn
  • Twitter
  • Facebook
  • Google
  • Telegram
  • Home
  • Glossary
  • News
  • Aims and Scope
  • Privacy Policy
  • Sitemap
This journal is licensed under a Creative Commons Attribution 4.0 International (CC-BY 4.0)

Powered by eJournalPlus